DATATRAK International

Datatrak Q3 Sales Drop by a Third, Loss Narrows

Tuesday, November 17, 2009 07:30 AM

Datatrak International, a technology and services company focused on eClinical solutions, reported third quarter revenues fell 34% to $1.55 million compared with the prior year quarter but its net loss narrowed.

More... »

Datatrak Cuts Loss in Q2

Wednesday, August 19, 2009 06:22 AM

Struggling eClinical company Datatrak improved its financial outlook in the second quarter, cutting its net loss to $(39,000), or $0.00 per share on a basic and diluted basis, compared to a net loss of $(16,000,000), or $(1.17) per share, during the same period last year.

More... »

Datatrak Delisted from NASDAQ

Wednesday, June 10, 2009 07:30 AM

Datatrak, a Cleveland-based  eClinical company, was delisted from the stock exchange after failing to meet NASDAQ's $2.5-million minimum stockholders' equity requirement.

More... »

Datatrak CEO Steps Down

Friday, January 23, 2009 10:08 AM

After 17 years with the eClinical company, Jeffrey Green has stepped down as CEO of struggling Datatrak in order to pursue “other opportunities,” the company announced Thursday.

More... »

Datatrak Looks for Strategic Alternatives

Wednesday, July 30, 2008 07:42 AM

Cleveland-based Datatrak International, a struggling electronic data capture (EDC) vendor, has retained Healthcare Growth Partners (HGP) as a strategic and financial advisor to assist its Board of Directors in evaluating a variety of potential opportunities directed at maximizing shareholder value.

More... »

Time To Embrace Paperless Clinical Trials

Wednesday, June 21, 2006 02:30 PM

When it comes to efficient drug development, pharmaceutical companies have a lot to learn. Recent research we conducted at CenterWatch suggests, however, that they might just be getting t he message, at least when it comes to clinical trials In a recent survey, we polled users of electronic data capture (EDC) software – the folks on the front line of research who conduct their clinical trials using this software – for their views on the factors most likely to prevent future drug development delays.

More... »